基于我的搜索结果，我现在将整理所有关于STAT6研究的核心发现和进展：

----
id: "delgado-ramirez2020_stat6_cancer"
title: "Signal transducer and activator of transcription 6 as a target in cancer therapy"
authors: ["Y Delgado-Ramirez"]
year: 2020
journal: "Journal of Clinical Medicine"
doi: "10.3390/jcm9051460"
citation_key: "delgado-ramirez2020"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7285805/"
content: |
  STAT6 inhibition decreases tumor cell proliferation, survival, adhesion, invasion and metastasis in experimental models and cancer cell lines. Recent inhibition studies have shown that targeting STAT6 signaling reduces tumor growth and/or metastasis in gastric cancer, breast cancer, and Lewis lung carcinoma models.

----
id: "fu2019_il4_stat6_lung"
title: "Activation of the IL-4/STAT6 Signaling Pathway Promotes Lung Cancer Progression"
authors: ["C Fu"]
year: 2019
journal: "Frontiers in Immunology"
doi: "10.3389/fimmu.2019.02638"
citation_key: "fu2019"
url: "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02638/full"
content: |
  IL-4/STAT6 signaling in CD11b+ cells promotes lung cancer progression by triggering an IL-4 positive feedback loop. This pathway enhances tumor growth through modulation of the tumor microenvironment and immune cell functions.

----
id: "liu2024_stat6_lncrna"
title: "STAT6/LINC01637 axis regulates tumor growth via autophagy"
authors: ["B Liu"]
year: 2024
journal: "Cell Death & Disease"
doi: "10.1038/s41419-024-07115-5"
citation_key: "liu2024"
url: "https://www.nature.com/articles/s41419-024-07115-5"
content: |
  The STAT6/LINC01637 axis promotes uveal melanoma progression via autophagy regulation and may serve as a potential therapeutic target. This study demonstrates the complex interplay between STAT6 signaling and non-coding RNAs in cancer progression.

----
id: "wills-karp2008_il4_il13_stat6"
title: "Untangling the Complex Web of IL-4– and IL-13–Mediated Signaling Pathways"
authors: ["M Wills-Karp"]
year: 2008
journal: "Journal of Immunology"
doi: "10.4049/jimmunol.181.8.5175"
citation_key: "wills-karp2008"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC4446705/"
content: |
  Phosphorylated STAT6 dimerizes, migrates to the nucleus, and binds to the promoters of IL-4– and IL-13–responsive genes such as those associated with IgE class switching. This pathway is central to Th2 immune responses and allergic inflammation.

----
id: "sharma2023_stat6_gof"
title: "Human germline heterozygous gain-of-function STAT6 variants cause severe allergic disease"
authors: ["M Sharma"]
year: 2023
journal: "Nature Immunology"
doi: "10.1038/s41590-023-01449-6"
citation_key: "sharma2023"
url: "https://pubmed.ncbi.nlm.nih.gov/36884218/"
content: |
  Identifies heterozygous gain-of-function variants in STAT6 as a novel autosomal dominant allergic disorder. These mutations lead to severe allergic dysregulation through enhanced IL-4/IL-13 signaling and represent a new class of inborn errors of immunity.

----
id: "smith2023_stat6_gof_variants"
title: "Gain-of-function STAT6 variants in severe allergic disease"
authors: ["TD Smith"]
year: 2023
journal: "Journal of Allergy and Clinical Immunology"
doi: "10.1016/j.jaci.2023.02.032"
citation_key: "smith2023"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10213836/"
content: |
  The interleukin 4R (IL-4R)-STAT6 axis plays a critical role in type-2 immunity, and its dysregulation plays a pathogenic role in different allergic diseases. Gain-of-function STAT6 variants represent a newly recognized mechanism for severe allergic phenotypes.

----
id: "zhou2017_stat6_structure"
title: "N4 DNA recognition by STAT6: structural and functional insights"
authors: ["X Zhou"]
year: 2017
journal: "Nucleic Acids Research"
doi: "10.1093/nar/gkx127"
citation_key: "zhou2017"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC5359187/"
content: |
  STAT6 as a transcription factor in the cytoplasm can form dimers upon phosphorylation. The STAT6 dimers then translocate into the nucleus to regulate gene expression. This study provides structural insights into STAT6-DNA interactions.

----
id: "chen2010_stat6_nuclear"
title: "Live Cell Imaging Reveals Continuous STAT6 Nuclear Trafficking"
authors: ["HC Chen"]
year: 2010
journal: "Journal of Biological Chemistry"
doi: "10.1074/jbc.M109.089342"
citation_key: "chen2010"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC2891132/"
content: |
  Specific phosphorylation of tyrosine 641 promotes STAT6 dimerization and its ability to bind DNA target sites. Live cell imaging demonstrates continuous nuclear-cytoplasmic shuttling of STAT6, providing insights into its dynamic regulation.

----
id: "he2023_stat6_aso"
title: "Inhibition of STAT6 with Antisense Oligonucleotides Enhances Antitumor Immunity"
authors: ["K He"]
year: 2023
journal: "Cancer Research"
doi: "10.1158/0008-5472.CAN-22-3655"
citation_key: "he2023"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC10099280/"
content: |
  STAT6 inhibition with antisense oligonucleotides reduces M2 macrophage tumor infiltration, enhances TH1 polarization, improves T cell and macrophage function, and demonstrates potent antitumor activity in preclinical models.

----
id: "binnemars-postma2018_stat6_tam"
title: "Targeting the Stat6 pathway in tumor-associated macrophages reduces tumor growth and metastatic niche formation in breast cancer"
authors: ["K Binnemars-Postma"]
year: 2018
journal: "FASEB Journal"
doi: "10.1096/fj.201700629R"
citation_key: "binnemars-postma2018"
url: "https://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.201700629R"
content: |
  Inhibition of the Stat6 pathway in tumor-associated macrophages is a vital therapeutic approach to attenuate tumor growth and metastasis by inhibiting TAM-induced protumorigenic and pro-metastatic functions.

----
id: "pastuszak-lewandoska2018_stat6_expression"
title: "The Expression Levels of IL-4/IL-13/STAT6 Signaling in Autoimmune Thyroid Diseases"
authors: ["D Pastuszak-Lewandoska"]
year: 2018
journal: "Journal of Immunology Research"
doi: "10.1155/2018/9215490"
citation_key: "pastuszak-lewandoska2018"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6132440/"
content: |
  STAT6 appears to be the main target for IL-4 and IL-13 and appears to be essential for Th1/Th2 balance during the autoimmunity response. This study highlights the role of STAT6 in autoimmune thyroid diseases.

----
id: "junttila2018_il4_il13_review"
title: "Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes"
authors: ["IS Junttila"]
year: 2018
journal: "Frontiers in Immunology"
doi: "10.3389/fimmu.2018.00888"
citation_key: "junttila2018"
url: "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.00888/full"
content: |
  Depending on the cell type, IL-4 and IL-13 both can activate STAT6. This comprehensive review details the complex signaling mechanisms of IL-4 and IL-13 through their receptor complexes and STAT6 activation.

----
id: "scott2023_il4_il13_stat6"
title: "IL-4 and IL-13 induce equivalent expression of traditional M2 markers in human macrophages"
authors: ["TE Scott"]
year: 2023
journal: "Scientific Reports"
doi: "10.1038/s41598-023-46237-2"
citation_key: "scott2023"
url: "https://www.nature.com/articles/s41598-023-46237-2"
content: |
  Activation of the type II receptor by IL-4 leads to activation of the JAK2/STAT3 pathway or TYK2/STAT6 pathway. This study demonstrates the functional equivalence of IL-4 and IL-13 in macrophage polarization through STAT6 signaling.

----
id: "chu2021_stat6_asthma"
title: "STAT6 Pathway Is Critical for the Induction and Function of Regulatory T Cells in Asthma"
authors: ["KH Chu"]
year: 2021
journal: "Frontiers in Immunology"
doi: "10.3389/fimmu.2020.615868"
citation_key: "chu2021"
url: "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.615868/full"
content: |
  Asthma is a chronic inflammatory disease characterized by allergic airway inflammation with increased mucus production and lung epithelium remodeling. The STAT6 pathway plays a critical role in regulatory T cell function in asthma pathogenesis.

----
id: "krishnamurthy2016_stat6_parp"
title: "STAT6 and PARP Family Members in the Development of T Cell-dependent Allergic Airway Inflammation"
authors: ["P Krishnamurthy"]
year: 2016
journal: "Immune Network"
doi: "10.4110/in.2016.16.4.201"
citation_key: "krishnamurthy2016"
url: "https://immunenetwork.org/DOIx.php?id=10.4110/in.2016.16.4.201"
content: |
  STAT6 is activated by the cytokines IL-4 and IL-13 to mediate the pathogenesis of allergic disorders such as asthma, atopic dermatitis, food allergy and allergic rhinitis. This study explores the interaction between STAT6 and PARP family members in allergic inflammation.

----
id: "gilead2025_stat6_partnership"
title: "Gilead and LEO Pharma Enter Into Strategic Partnership for STAT6 Program Development"
authors: ["Gilead Sciences"]
year: 2025
journal: "Company Press Release"
citation_key: "gilead2025"
url: "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases"
content: |
  Gilead will acquire LEO Pharma's comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. This partnership aims to accelerate development of oral STAT6 programs for multiple inflammatory diseases.

----
id: "recludix2024_stat6_inhibitor"
title: "Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor"
authors: ["Recludix Pharma"]
year: 2024
journal: "Company Press Release"
citation_key: "recludix2024"
url: "https://recludixpharma.com/recludix-pharma-announces-development-candidate-nomination-of-first-in-class-oral-stat6-inhibitor-for-inflammatory-diseases-and-achievement-of-significant-milestone-under-collaboration-with-sanofi/"
content: |
  Recludix is advancing STAT6 inhibitors from preclinical research and development until the start of Phase 2 clinical trials. The company is working with Sanofi to advance a STAT6 inhibitor into clinical trials for inflammatory diseases.

----
id: "kymera2024_stat6_degrader"
title: "Kymera Therapeutics Presents Preclinical Data for STAT6 Degrader KT-621"
authors: ["Kymera Therapeutics"]
year: 2024
journal: "Company Press Release"
citation_key: "kymera2024"
url: "https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-presents-preclinical-data-stat6-and-tyk2"
content: |
  KT-621 is an oral STAT6 degrader that has the potential to provide biologics-like activity with oral small molecule profiles. It represents the first STAT6 targeted medicine to enter clinical development, with potential applications in multiple inflammatory and allergic diseases.

----
id: "zhihuiya2024_stat6_protac_china"
title: "全球首款STAT6 PROTAC药物开启临床试验"
authors: ["智慧芽"]
year: 2024
journal: "智慧芽新闻"
citation_key: "zhihuiya2024"
url: "https://www.zhihuiya.com/news/info_8546.html"
content: |
  KT-621是全球目前唯一进入临床试验阶段的针对STAT6蛋白的裂解嵌合体（PROTAC）。这项研究详情已在ClinicalTrials官方网站公布，涉及中国及国际多个研究中心。这标志着STAT6靶向治疗的重要里程碑。

----
id: "bydrug2024_stat6_china_review"
title: "明星靶点STAT6：小分子抑制剂与PROTAC降解剂"
authors: ["ByDrug医药新闻"]
year: 2024
journal: "ByDrug医药新闻"
citation_key: "bydrug2024"
url: "https://bydrug.pharmcube.com/news/detail/a06c13c9c54080a33becf9cadaa75865"
content: |
  国内对STAT6靶点研究日益重视，多家中国药企正在开发STAT6小分子抑制剂和PROTAC降解剂。陶莎莎/杨友静团队揭示STAT6激活可抑制线粒体自噬，引发线粒体功能障碍和铁死亡，为STAT6在肿瘤中的作用提供了新机制。

----
id: "yang2019_jak_stat_china"
title: "JAK/STAT信号通路在肺癌中的研究进展"
authors: ["杨昕"]
year: 2019
journal: "中国肺癌杂志"
doi: "10.3779/j.issn.1009-3419.2019.02.01"
citation_key: "yang2019"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC6348154/"
content: |
  JAK家族与STAT家族的多个成员共同构成了多条信号通路，如JAK1/STAT6、JAK2/STAT3和JAK2/STAT5等。该综述总结了JAK/STAT信号通路在肺癌中的研究进展，特别关注了STAT6在肺癌发生发展中的作用。

----
id: "cas2019_stat6_acetylation_china"
title: "上海营养与健康研究所合作发现Stat6乙酰化调控抗肿瘤免疫"
authors: ["于涛", "甘叔诚", "朱清晨"]
year: 2019
journal: "中国科学院上海营养与健康研究所"
citation_key: "cas2019"
url: "https://shb.cas.cn/kydt2024/kjjz2024/201909/t20190926_5401194.html"
content: |
  研究发现Stat6乙酰化修饰在抗肿瘤免疫中发挥重要作用。靶向Stat6乙酰化修饰或者Trim24活性可以作为肿瘤免疫干预的潜在分子靶标。这项研究为STAT6的翻译后修饰调控提供了新的视角。